Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2016, Article ID 9596123, 5 pages
http://dx.doi.org/10.1155/2016/9596123
Case Report

A Practical Method for No-Reflow Treatment

1Cardiology Department, Numune Education and Research Hospital, Cardiology Department, 06100 Ankara, Turkey
2Cardiology Department, Dr. Nafiz Korez State Hospital, 06100 Ankara, Turkey

Received 22 November 2015; Accepted 18 January 2016

Academic Editor: Manabu Shirotani

Copyright © 2016 Mustafa Cetin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Ndrepepa, K. Tiroch, M. Fusaro et al., “5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction,” Journal of the American College of Cardiology, vol. 55, no. 21, pp. 2383–2389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Q. Guo, L. Sheng, X. Lei, and W. Shu, “Pharmacological and physical prevention and treatment of no-reflow after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction,” Journal of International Medical Research, vol. 41, no. 3, pp. 537–547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Wilson and D. Eccleston, “How to manage no reflow phenomenon with local drug delivery via a rapid exchange catheter,” Catheterization and Cardiovascular Interventions, vol. 77, no. 2, pp. 217–219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M.-R. Movahed and G. Baweja, “Distal administration of very high doses of intracoronary adenosine for the treatment of resistant no-reflow,” Experimental and Clinical Cardiology, vol. 13, no. 3, pp. 141–143, 2008. View at Google Scholar · View at Scopus
  5. F. S. Resnic, M. Wainstein, M. K. Y. Lee et al., “No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention,” American Heart Journal, vol. 145, no. 1, pp. 42–46, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Galasso, S. Schiekofer, C. D'Anna et al., “No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives,” Angiology, vol. 65, no. 3, pp. 180–189, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Jaffe, A. Dick, and B. H. Strauss, “Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach,” JACC: Cardiovascular Interventions, vol. 3, no. 7, pp. 695–704, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Marzilli, E. Orsini, P. Marraccini, and R. Testa, “Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction,” Circulation, vol. 101, no. 18, pp. 2154–2159, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Amit, C. Cafri, S. Yaroslavtsev et al., “Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial,” American Heart Journal, vol. 152, no. 5, pp. 887.e9–887.e14, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Maluenda, I. Ben-Dor, C. Delhaye et al., “Clinical experience with a novel intracoronary perfusion catheter to treat no-reflow phenomenon in acute coronary syndromes,” Journal of Interventional Cardiology, vol. 23, no. 2, pp. 109–113, 2010. View at Publisher · View at Google Scholar · View at Scopus